Document |
Document Title |
WO/2024/046253A1 |
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...
|
WO/2024/044848A1 |
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
WO/2024/048778A1 |
The present invention relates to an aryltetrahydropyridine compound represented by formula (1) or a salt thereof. [In formula (1), Q represents Q-1, etc.; J represents J-1, etc.; G represents G-1, etc.; R1 represents a halo(C1-C6)alkyl, ...
|
WO/2024/041397A1 |
Provided 4-pyrazolyl-N-heteroarylpyrimidin-2-amine compounds as potent TYK2/JAK1/JAK2 inhibitors with low systemic exposures when applied topically. Thus, these compounds, and compositions are useful as topical treatment of dermatologica...
|
WO/2024/044344A1 |
The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
WO/2024/044730A1 |
The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
WO/2024/042007A1 |
The invention relates to substituted bicycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans,...
|
WO/2024/040768A1 |
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acce...
|
WO/2024/042043A1 |
This invention relates to a synthetic method for the preparation of compound (1) and precursors thereof. Compound (1) is prepared via reaction of isoxazole (2) with phenylether (R)-3-ONa.
|
WO/2024/042146A2 |
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufa...
|
WO/2024/044757A1 |
The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
|
WO/2024/039689A1 |
Provided herein are compounds of formula (I) that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).
|
WO/2024/038282A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, Y and B are as ...
|
WO/2024/040190A1 |
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
|
WO/2024/040155A1 |
Disclosed herein are isoxazolidine compounds and their use as receptor-interacting protein kinase 1 inhibitor, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
|
WO/2024/040267A2 |
The present disclosure is directed to N-(3-substituted-chroman-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-
amine compounds useful as PINK1 modulators, compounds useful in preparing N-(3-substituted-chroman-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-
ami...
|
WO/2024/039056A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
|
WO/2024/039886A1 |
Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with ce...
|
WO/2024/039250A1 |
The present invention relates to a new class of methanogen inhibitors for ruminants. The invention also extends to the use of such compounds in ruminants to reduce methane production in the rumen and/or to enhance productivity in the rum...
|
WO/2024/034657A1 |
The present invention addresses the problem of providing a pharmaceutical composition for cancer treatment of colorectal cancer and/or lung cancer. The present inventors have studied compounds useful as an active ingredient for a pharm...
|
WO/2024/032529A1 |
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...
|
WO/2024/035950A1 |
Provided are compounds of the Formula (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
|
WO/2024/036176A1 |
Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment...
|
WO/2024/032501A1 |
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, a...
|
WO/2024/032715A1 |
Disclosed is a compound having a structure represented by formula (I). The compound has excellent antiviral activity against orthopoxvirus, has multiple advantages compared with a marketed drug Tecovirimat, and has important development ...
|
WO/2024/032584A1 |
The present invention relates to a protein tyrosine kinase inhibitor for treating protein tyrosine kinase-mediated proliferative diseases or symptoms, such as ocular diseases and malignant tumors accompanied by pathological neoangiogenes...
|
WO/2024/031089A1 |
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
|
WO/2024/027795A1 |
An antibody-drug conjugate containing an Myc protein degradation agent bioactive compound, a preparation method therefor, and use thereof in preventing and/or treating diseases related to abnormal cell activity, including but not limited...
|
WO/2024/027703A1 |
Provided are a PRMT5 inhibitor, and a preparation method therefor and a use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a use thereof in ...
|
WO/2024/027694A1 |
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...
|
WO/2024/026536A1 |
The present disclosure relates to a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. Th...
|
WO/2024/027767A1 |
The present invention relates to a herbicide composition comprising a uracil compound comprising at least one carboxylate fragment represented by formula (I) and at least one herbicide active compound, and a use of the herbicide composit...
|
WO/2024/027641A1 |
An IRAK4 inhibitor composition, a preparation method therefor and use thereof. The composition comprises: (i) a compound of formula I, a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof; (ii) a diluent; (iii) a disin...
|
WO/2024/028795A1 |
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon l...
|
WO/2024/028604A1 |
The present invention relates to compounds of formula (I) as prostaglandin E2 receptor 4 (EP4) agonists for use in methods of treatment of gastrointestinal and pulmonary diseases or disorders. The present disclosure provides exemplary co...
|
WO/2024/029638A1 |
The present invention relates to a series of novel heterocyclyl-phenyl-methylamine derivatives, a preparation method therefor, and a use thereof for prevention, alleviation, or treatment of multiple sclerosis.
|
WO/2024/028605A1 |
The invention relates to a class of ortho-substituted difunctional benzoxazine compounds useful as curatives, as well as methods of preparation, and uses thereof. The ortho-substituted difunctional benzoxazine compounds comprise two benz...
|
WO/2024/029583A1 |
The present invention relates to: a compound represented by formula (I) (wherein Ar1 and Ar2 may be the same as or different from each other, and each represent a substituted or unsubstituted aromatic group; L1 represents a direct bond o...
|
WO/2024/028365A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
WO/2024/027800A1 |
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...
|
WO/2024/029613A1 |
Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer. The present inventors carried out investigations with regard to compounds useful as an active ingredient in a pharmac...
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
WO/2024/023128A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2024/023287A1 |
The present invention relates to a compound of general formula (I). The invention further relates to the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological...
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
WO/2024/026484A2 |
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
|
WO/2024/022481A1 |
The present invention belongs to the technical field of medicines. Disclosed are phenyl-substituted dihydronaphthyridine compounds and preparation and use thereof. The compound disclosed by the present invention is represented by formula...
|
WO/2024/022294A1 |
Disclosed are a spirochiral platinum(ii) and palladium(ii) complex circularly polarized luminescent material, and a use thereof. The formation of the spirochiral metal complex molecule can autonomously induce an entire tetradentate ligan...
|
WO/2024/026061A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject i...
|
WO/2024/022475A1 |
The present invention belongs to the technical field of pharmaceutical synthesis technology and relates to a pyridyl-substituted thioglycolide intermediate for pharmaceutical use and its preparation method and use. In particular, the pre...
|